Arbutus Biopharma | Investor Presentation Deck | 28 slides · page 18 of 28
The slide outlines two distinct study arms involving AB-729, VTP-300, and Nivolumab, with a primary focus on safety and reactogenicity.
Pitch deck · appendix_methodology · plan_implementation · dense density
Slide locked Sign in to view
Slide schematic 4/4
diagram 1/1 list 1/1 paragraph 1/1 title 1/1
Components 4
timeline bullet paragraph headline
Tools 0
∅
No tools
No canon tool match is anchored to this slide.
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 1